hotspot -WSS

hotspot

author：knowledge 2025-09-27 10:01:28 - browse：96268

An experimental drug from Insmed Incorporated successfully reduced lung problems among patients with an airway disease in a closely watched Phase 3 trial, sending the company’s share price soaring early Tuesday.

The drug, brensocatib, reduced so-called pulmonary exacerbations by roughly 20% versus placebo in patients with bronchiectasis, hitting the trial’s primary endpoint. The trial, called the ASPEN study, tested two dosages of the drug, and the company said both significantly cut rates of pulmonary exacerbations.

Insmed shares more than doubled in pre-market trading. Analysts have forecasted that brensocatib could lead to billions of dollars in annual sales if approved.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Spinal cord stimulation reduces pain in amputees, study finds

hotspot

explore

WSS

Trump indictment: Who are the 'co

Hyundai and Kia recall nearly 92,000 vehicles and tell owners to park them outside due to fire risk

Congenital heart disease patients face new threat of heart failure

What causes an itch? Researchers may have solved the mystery

Roche to buy Carmot Therapeutics, developer of obesity drugs

Physician groups backed by private equity giant lobby on mergers

entertainment

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

DIEP, the 'gold standard' of breast reconstruction, is under threat

Roche to buy Carmot Therapeutics, developer of obesity drugs

Hepatitis C has a cure — but many Americans still lack access to it

Hyundai and Kia recall nearly 92,000 vehicles and tell owners to park them outside due to fire risk

In age of alternative facts, a scholarly course on calling out crap

SCOTUS to consider access to abortion pill mifepristone

Hollywood unions extend contract negotiations for actors

5 important ways Henrietta Lacks changed medical science

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

New safety details link Apellis eye drug to rare cases of blindness

knowledge

No plane should take off without an EpiPen onboard

Why sickle cell disease is getting the first CRISPR treatment

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

What the airline industry can learn from medicine

Spinal cord stimulation reduces pain in amputees, study finds

Radiology is caught between AI's potential and concern for patients

explore

hotspot

explore

hotspot